PIK3CA inhibitor

DRUG CLASS:

PIK3CA inhibitor

News alerts, weekly reports and conference planners

Related drugs:

PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	copanlisib Sensitive: A1 - Approval copanlisib Sensitive : A1	copanlisib Sensitive: A1 - Approval copanlisib Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	copanlisib Sensitive: A2 - Guideline copanlisib Sensitive : A2	copanlisib Sensitive: A2 - Guideline copanlisib Sensitive : A2
PIK3CA exon 20 mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA exon 20 mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
PIK3CA exon 7 mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA exon 7 mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
PIK3CA exon 9 mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA exon 9 mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
ESR1 mutation + PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Resistant: A2 - Guideline alpelisib Resistant : A2	alpelisib Resistant: A2 - Guideline alpelisib Resistant : A2
PIK3CA mutation + HR positive + HER-2 negative	Male Breast Cancer	PIK3CA mutation + HR positive + HER-2 negative	Male Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B
PIK3CA mutation	HER2 Negative Breast Cancer	PIK3CA mutation	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA E542K + HR positive	HER2 Negative Breast Cancer	PIK3CA E542K + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA H1047X	HER2 Negative Breast Cancer	PIK3CA H1047X	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA E545X	HER2 Negative Breast Cancer	PIK3CA E545X	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	rituximab + copanlisib Sensitive: B - Late Trials rituximab + copanlisib Sensitive : B	rituximab + copanlisib Sensitive: B - Late Trials rituximab + copanlisib Sensitive : B
CD20 positive	Non-Hodgkin’s Lymphoma	CD20 positive	Non-Hodgkin’s Lymphoma	rituximab + copanlisib Sensitive: B - Late Trials rituximab + copanlisib Sensitive : B	rituximab + copanlisib Sensitive: B - Late Trials rituximab + copanlisib Sensitive : B
PIK3CA N345K + PIK3CA N1044K	Breast Cancer	PIK3CA N345K + PIK3CA N1044K	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA G106_108del	Breast Cancer	PIK3CA G106_108del	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA R38C	Breast Cancer	PIK3CA R38C	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA Q75E	Breast Cancer	PIK3CA Q75E	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA N345K	Breast Cancer	PIK3CA N345K	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
CD20 positive	Lymphoma	CD20 positive	Lymphoma	rituximab + copanlisib Sensitive: B - Late Trials rituximab + copanlisib Sensitive : B	rituximab + copanlisib Sensitive: B - Late Trials rituximab + copanlisib Sensitive : B
FGFR1 mutation	Breast Cancer	FGFR1 mutation	Breast Cancer	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B
TP53 mutation	Breast Cancer	TP53 mutation	Breast Cancer	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B
PTEN mutation	Breast Cancer	PTEN mutation	Breast Cancer	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + pertuzumab + alpelisib Sensitive: B - Late Trials trastuzumab + pertuzumab + alpelisib Sensitive : B	trastuzumab + pertuzumab + alpelisib Sensitive: B - Late Trials trastuzumab + pertuzumab + alpelisib Sensitive : B
PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer	PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: C1 - Off-label alpelisib Sensitive : C1	alpelisib Sensitive: C1 - Off-label alpelisib Sensitive : C1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	inavolisib Sensitive: C2 – Inclusion Criteria inavolisib Sensitive : C2	inavolisib Sensitive: C2 – Inclusion Criteria inavolisib Sensitive : C2
PIK3CA mutation	Gastric Cancer	PIK3CA mutation	Gastric Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2

PIK3CA inhibitor

PIK3CA inhibitor

Associations(150)

Associations
(150)